Finanzen von Eikon Therapeutics Inc (EIKN)EIKNEikon Therapeutics Inc

In the context of the broader market, EIKN competes directly with industry leaders such as ASPI and BLSM. With a market capitalization of $598.52M, it holds a significant position in the sector. When comparing efficiency, EIKN's gross margin of N/A stands against ASPI's 28.89% and BLSM's N/A. Such benchmarking helps identify whether Eikon Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Eikon Therapeutics has reported substantial net losses, with Q2 2026 net income of -88,409,000 USD and a current ratio of 9.89, indicating liquidity issues. The company has a forward P/E of 0, reflecting no expected earnings growth in the near term.